Gyre Therapeutics Inc (GYRE) financials
Gyre Therapeutics revenue and earnings by year
Gyre Therapeutics's revenue was $117 million in the fiscal year to December 31, 2025, up 10.2% from the year before. Net income was $5.03 million, 4.3% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 87.9% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 8 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 117 | 106 | 113 | 102 | 7 | 21 | 1 | 0 |
| Revenue growth | 10.2% | -6.8% | 10.9% | 1294.0% | -65.0% | 1957.8% | 155.1% | — |
| Gross profit | 111 | 102 | 109 | 97 | -0 | 12 | — | — |
| Gross margin | 95.4% | 96.3% | 95.9% | 95.3% | -0.6% | 56.3% | — | — |
| Operating income | 11 | 16 | -67 | 9 | -88 | -57 | -22 | -20 |
| Operating margin | 9.9% | 15.3% | -59.3% | 9.0% | -1197.8% | -273.9% | -2143.6% | -5117.3% |
| Net income | 5 | 12 | -93 | 2 | -88 | -56 | -22 | -17 |
| Net margin | 4.3% | 11.4% | -81.9% | 2.3% | -1198.3% | -268.5% | -2118.0% | -4246.9% |
| Diluted EPS | $0.02 | — | -$1.41 | $0.02 | — | — | — | — |
| Free cash flow | -0 | -6 | 18 | 6 | -85 | -55 | -20 | -19 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open GYRE in Markets.
How Gyre Therapeutics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Gyre Pharmaceuticals | $29.1M | 100.0% |
| Gyre | $8.00K | 0.0% |
See also: GYRE returns
No forecast, no recommendation. This page describes Gyre Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.